Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis.
about
New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitorsImprovement in latent variable indirect response modeling of multiple categorical clinical endpoints: application to modeling of guselkumab treatment effects in psoriatic patients.Establishing Good Practices for Exposure-Response Analysis of Clinical Endpoints in Drug Development.First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis.
P2860
Information contributed by meta-analysis in exposure-response modeling: application to phase 2 dose selection of guselkumab in patients with moderate-to-severe psoriasis.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Information contributed by met ...... moderate-to-severe psoriasis.
@en
Information contributed by met ...... moderate-to-severe psoriasis.
@nl
type
label
Information contributed by met ...... moderate-to-severe psoriasis.
@en
Information contributed by met ...... moderate-to-severe psoriasis.
@nl
prefLabel
Information contributed by met ...... moderate-to-severe psoriasis.
@en
Information contributed by met ...... moderate-to-severe psoriasis.
@nl
P2093
P2860
P1476
Information contributed by met ...... moderate-to-severe psoriasis.
@en
P2093
Chuanpu Hu
Honghui Zhou
Yanli Zhuang
Yasmine Wasfi
P2860
P2888
P304
P356
10.1007/S10928-014-9360-6
P577
2014-05-23T00:00:00Z